NIH-funded cancer study
This article was originally published in The Tan Sheet
Executive Summary
The National Institutes of Health awards Omaha, Neb.-based Creighton University $4 million to continue a "landmark" study linking vitamin D to reduced cancer risk. The original study, headed by Joan Lappe and reported in June 2007, showed for the first time in a clinical setting that postmenopausal women consuming calcium and vitamin D3 supplements at nearly three times the recommended levels could reduce the risk of cancer by 60-77 percent, the university says Jan. 26. "We must now confirm these findings with a clinical trial specifically designed to look at calcium, vitamin D and cancer," Lappe says. "Confirmation is necessary in order to have evidence solid enough to change public policy regarding intake levels for vitamin D." The four-year study begins in April and will follow 2,300 healthy, postmenopausal women from Nebraska
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.